Rivoceranib, selected as ‘The Best of ESMO 2019’ (10/02/2019)
At ESMO(European Society for Medical Oncology), which ended this morning, selected Rivoceranib’s ANGEL Study as ‘The Best of ESMO 2019’.
ESMO is one of the world's most prestigious societies with ASCO, and 3,904 papers were submitted to ESMO.
Keytruda, Opdivo and Rivoceranib were selected as The Best of ESMO 2019. Keytruda and Opdivo are the blockbuster drugs that generated billions of dollars
in sales last year. Considering that the Angel Study of Elevar was selected as The Best of ESMO 2019, it is considered as good news for the future of Rivoceranib
We would like to share these achievements and joys with our shareholders, and we will make a great progress toward our goal of becoming the first company in Korea
to launch a global anticancer drug.